Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
Search results
529 results
-
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
In development [GID-TA10418] Expected publication date: TBC
-
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
In development [GID-TA10402] Expected publication date: TBC
-
Nintedanib for untreated malignant pleural mesothelioma (ID1424)
In development [GID-TA10359] Expected publication date: TBC
-
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498
In development [GID-TA10420] Expected publication date: 23 June 2021
-
Pancreatic cancer - capecitabine [ID389]
In development [GID-TAG394] Expected publication date: TBC
-
Melanoma (advanced and metastatic) - temozolomide [ID316]
In development [GID-TAG401] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
In development [GID-TAG406] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: 01 October 2014
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
In development [GID-TAG372] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Prostate cancer - intensity modulated radiotherapy [ID17]
In development [GID-TAG396] Expected publication date: TBC
-
Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]
In development [GID-TAG496] Expected publication date: TBC
-
Colon cancer (adjuvant) - irinotecan [ID379]
In development [GID-TAG380] Expected publication date: TBC
-
Head and neck cancer - contusugene ladenovec [ID76]
In development [GID-TAG407] Expected publication date: TBC
-
Lung cancer (non-small cell) - afatinib [ID357]
In development [GID-TAG422] Expected publication date: TBC
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
In development [GID-TAG494] Expected publication date: TBC
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
In development [GID-TAG330] Expected publication date: TBC
-
Prostate cancer (hormone refractory) - atrasentan [ID390]
In development [GID-TAG379] Expected publication date: TBC
-
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
In development [GID-TAG300] Expected publication date: TBC
-
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]
In development [GID-TAG440] Expected publication date: TBC
-
Diabetes - buccal insulin [ID311]
In development [GID-TAG244] Expected publication date: TBC
-
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]
In development [GID-TAG410] Expected publication date: TBC
-
Clostridium difficile associated diarrhoea - tolevamer [ID378]
In development [GID-TAG389] Expected publication date: TBC
-
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]
In development [GID-TAG405] Expected publication date: TBC
-
Cardiac transplantation (rejection) - everolimus [ID114]
In development [GID-TAG232] Expected publication date: TBC
-
Heart failure (acute decompensated) - nesiritide [ID384]
In development [GID-TAG376] Expected publication date: TBC
-
Atrial fibrillation - idraparinux sodium [ID375]
In development [GID-TAG383] Expected publication date: TBC
-
Venous thromboembolism (recurrent) - idraparinux sodium [ID395]
In development [GID-TAG384] Expected publication date: TBC
-
Psoriatic arthritis (moderate to severe) - leflunomide [ID391]
In development [GID-TAG385] Expected publication date: TBC
-
Diabetic retinopathy - ruboxistaurin [ID382]
In development [GID-TAG386] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
In development [GID-TAG388] Expected publication date: TBC
-
Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]
In development [GID-TAG391] Expected publication date: TBC
-
Juvenile idiopathic arthritis - adalimumab [ID385]
In development [GID-TAG400] Expected publication date: TBC
-
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
In development [GID-TAG416] Expected publication date: TBC
-
Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]
In development [GID-TAG408] Expected publication date: 01 May 2011
-
Atrial fibrillation - ximelagatran [ID376]
In development [GID-TAG377] Expected publication date: TBC
-
Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]
In development [GID-TAG415] Expected publication date: TBC
-
Pembrolizumab for previously treated endometrial cancer [ID1205]
In development [GID-TA10243] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
In development [GID-TA10121] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
In development [GID-TA10473] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC